NEW SLANT ON HYPERLIPIDEMIA: PREVENTION BY VITAMIN B-3 AND COMMON FRUIT ZIZIPHUS JUJUBA
Coronary artery disease (CAD) is complication of primary or secondary hyperlipidemia. Etiological factors for hyperlipidemia include inherited genetic defects in low density lipoproteins (LDLs), persons accustomed to sit for prolong time, cigarette smoking, diabetes mellitus, and hypertension. This research workâ€™s aim was to compare hypolipidemic features of an allopathic agent vitamin B-3 and another medicinal plant Z. Jujuba. Study was conducted from January 2016 to June 2016 at Jinnah Hospital Lahore, Pakistan. 60 male and female hyperlipidemic patients age range from 20 to 70 years were selected from the hospital. Written and explained consent was taken from all patients. They were divided in two groups. Group-I was advised to take two grams vitamin B-3 in divided doses for the period of two months. Group-II was advised to take 500 grams of fruit Z. Jujuba daily for 60 days per their convenience. Their initial LDL and HDL cholesterol was determined by Friedwaldâ€™s formula. After 60 days therapy, their post treatment lipid profile was measured and mean values with Â± SD were analyzed biostatistically by using SPSS version 2; 2010. Group-I which was on vitamin B-3 their LDL cholesterol decreased significantly and HDL cholesterol was increased significantly. In group-II patients LDL cholesterol was decreased significantly but HDL increase was not significant with p-value of >0.05. It was concluded from the research study that vitamin B-3 is potent hypolipidemic agent as compared to medicinal plant Z. Jujuba.
2. Holmes CL, Schulzer M, Mancini GB. Hypolipidemic drugs for CAD. Lipid Res 2014;13(7):233-9.
3. Foulaw JU, Miller KW, Small DM. Surface-to-core and interparticle equilibrium distributions of triglyceride-rich lipoprotein lipids. J Biol Chem 2016;258:13772-84.
4. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Af J Cardiol 2015;81:13-7.
5. Thompson GR. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Afr Heart J 2014;19(2):34-40.
6. Parkal CS, Gordon DJ. Cholesterol lowering agents are true drugs for CAD. Lipid Res 2015;12(6):119-22.
7. Jatendaar TL, Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: in Sudan. Bio Res 2014;30(9):1212-7.
8. Gaw CL, Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Bioch J 2015;308:373-8.
9. Lokavi JK, McGill HC Jr, McMahan CA. Pathobiological Determinants of Atherosclerosis and its cure. J Physiol 2016;13(9):177-9.
10. McGill HC Jr, McMahan CA, Zieske AW, Sloop GD, Walcott JV. Vitamin B-3 (Niacin) is useful but? Arterioscler Thromb Vasc Biol 2014;20:1998-2004.
11. Takeichi S, Yukawa N, Nakajima Y, Osawa M, Saito T, Seto Y, Nakano T, Saniabadi AR, Adachi M, Wang T, Nakajima K. Association of plasma triglyceride-rich lipoprotein remnants with coronary atherosclerosis in cases of sudden cardiac death. Cl Lipid Res 2013;19(5):333-9.
12. Polasa TR, Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia and their treatment options. J cl Res 2015;10(5):222-8.
13. Saew TR, Law MR. Lowering heart disease risk with cholesterol reduction. J cl Cardiol 2014;19:118-20.
14. Jalui J, Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. J Physiol AFR 2013;18(7):111-8.
15. Lowaree T, Kuchinskiene Z, Carlson LA. Statins and Fibrates: are these safe hypolipidemic medicines?. J Cardiol 2014;12(7):345-8.
16. KY Ruha, NJ Ramaj, Pk Lawal, UY Oraal. Herbs as Hypolipidemic agents for CAD cure. Lipid Res J 2015;34(4):1083-96.
17. McGill HC Jr, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of herbal saponins on lipids. Arterioscler Thromb Vasc Biol 2015;17:95-106.
18. Qaluiy KI, Weisgraber KH, Innerarity TL, Rall SC Jr, Mahley RW. Herbal medicine for plasma lipids. Pharma Res 2013;23(8):222-9.
19. Lopara T, Koren E, Corder C, Mueller G, Centurion H, Hallum G. Active ingredients of Z Jujuba. Pharma plant Res 2012;19(3):289-94.
20. Palsy TR, Grundy SM. Cholesterol-lowering trials by plants. J pharma 2013;18(6):712-7.
21. Laralaoi J, Karpe F, Boquist S, Tang R, Bond GM. Ziziphus jujuba for lipid therapy. J pharmacog 2013;18(2):100-2.
22. Moki LT, Havel RJ. Medicinal herbs with good pharmacological effects. J Ph Res 2014;10(1):16-20.
23. Palve TI , Torela CK, Breslow JL. Vitamin B-3 for hyperlipidemia can prevent CAD. J Pharmacol 2014;12(6):213-9.
24. Salouit E , Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Pfeffer MA, Braunwald E. Niacin or Vitamin B-3 is not only vitamin: it is cure too for hyperlipidemia. Circulation 2012;102:1886-92.
25. Mao Ki , ordestgaard BG, Lewis B. HDL cholesterol for hyperlipidemia: cause and treatment. Atherosclerosis 2014;87:39-46.
26. Grams ET, Law MR, Wald NJ, Thompson SG. Mode of action of vitamin B-3 for hypolipidemic actions. Cl Nut. 2013; 308:367-72.
27. Yulkat Y, Tatami R, Mabuchi H, Ueda K, Ueda R. Medicinal herb for Hyperlipidemia treatment. J Pharmacog 2013;12(2):116-9.
28. Saloiu TL, Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Use of Ziziphus Jujuba for LDL and HDL cholesterol. Res J Lipids 2016;12(3):177-9.
29. Mekawali PO, Mahley RW, Weisgraber KH, Innerarity TL, Rall SC Jr. Medicinal herbs for treatment of high plasma LDL particles. J Pharma Ther 2014;265:78-83.
30. John DB , Toor M, Katchalsky A, Agmon J, Allalouf D. Z Jujuba inhibit enterohepatic circulation.J Pharma Res 2016;22:265-7.
31. Suleman T, Fatima H, Muraka B, Farhad S. Herbs and fatty foods may cause severe adverse effects in treating hyperlipidemia. Pharma J Ther 2014;14(4):266-9.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).